{
 "cells": [
  {
   "attachments": {},
   "cell_type": "markdown",
   "id": "6dac9fe4",
   "metadata": {},
   "source": [
    "# Correlating small-cap pharmaceutical drug companies' stock prices with the FDA drug approval process\n",
    "CS 198-134: Introduction to Quantitative Finance Final Project\n",
    "\n",
    "Presented by Cyprian Zander, Enmanual Felix Pena, Jeet Sandhu, Pranay Rajpaul, Shangdian Han"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "id": "344e43ed",
   "metadata": {},
   "source": [
    "## Abstract\n",
    "\n",
    "The pharmaceutical industry is a crucial sector of the global economy that plays a significant role in advancing healthcare and treating illnesses. The industry's growth and sustainability can be attributed to a steady stream of new drugs and therapies that address a range of diseases and health conditions. However, bringing a new drug to market is a complex and costly process that takes an average of 10-15 years and can cost over $1 billion in research and development. Moreover, the vast majority of drugs fail in the early testing phases, never making it past the preliminary stages and into clinical testing. As a result, significant financial resources must continually be invested in the process of developing new drugs and therapies. This investment is essential for companies to maintain a competitive edge in the industry and to stay ahead of the curve in terms of innovation and discovery.\n",
    "\n",
    "Pharmaceutical companies, especially smaller ones, are known to have highly volatile stock prices due to a variety of factors. Since the development of new drugs and therapies is a complex and costly process, it is subject to a range of uncertainties, including regulatory hurdles, clinical trial results, and patent expirations. As a result, the stock prices of these companies can be highly sensitive to changes in market sentiment and news related to drug development and approval processes.\n",
    "\n",
    "Recognizing trends in price fluctuations in pharmaceutical companies could yield a high Sharpe ratio trading strategy. This is because these companies often experience significant price swings in response to news related to their drug development pipelines, clinical trial results, and FDA drug approvals. By identifying patterns in these price movements, investors could potentially develop a trading strategy that generates good returns with low risk.\n",
    "\n",
    "For example, one significant determinant of price changes in pharmaceutical companies is the FDA drug approval process. The FDA is responsible for evaluating the safety and efficacy of new drugs before they can be marketed and sold to the public. The approval process can have a significant impact on a pharmaceutical company's stock price. If the FDA approves a new drug, it can lead to a significant increase in a company's stock price, as investors perceive the approval as a sign of the drug's potential commercial success. Conversely, if the FDA rejects a new drug, it can lead to a significant decline in a company's stock price, as investors perceive the rejection as a sign of the drug's potential commercial failure.\n",
    "\n",
    "The highly volatile stock prices of pharmaceutical companies could lead to high Sharpe ratios for specific trading strategies. For instance, a trading strategy that takes advantage of the price movements before and after an FDA drug approval could potentially generate high returns with relatively low risk. By buying the stock before the FDA approval and selling it shortly after the approval, traders could potentially capture the price increase and earn a profit. Similarly, by shorting the stock before the FDA rejection and covering the position after the rejection, traders could potentially capture the price decline and earn a profit.\n",
    "\n",
    "This report will address how analyzing and leveraging the news on FDA drug approvals for small-cap pharmaceutical companies can be an effective way to maximize the Sharpe ratio for trading strategies involving pharmaceutical companies. \n",
    "\n",
    "Our data will be based on drug approvals from January, 2018 to December 2022.\n",
    "\n",
    "## Research\n",
    "\n",
    "##### FDA Drug Approval Process\n",
    "\n",
    "To understand the observations we are tracing to stock price, a general understanding of the full FDA approval process is necessary. This research is taken from drugwatch.com and the fda.gov website.\n",
    "\n",
    "https://www.drugwatch.com/fda/approval-process/\n",
    "\n",
    "https://www.fda.gov/patients/drug-development-process/step-3-clinical-research\n",
    "\n",
    "<br />When wanting to bring a new drug to market, companies must file a **New Drug Application, or NDA**.\n",
    "\n",
    "**Incentive for pharmaceutical company**\n",
    "<br />A new patent is good for 20 years from the date the application is filed in the U.S.\n",
    "\n",
    "**Expedited review process**\n",
    "<br />Prescription Drug User Fee Act (PDUFA) allows the FDA to collect fees from companies to expedite the drug-approval process.\n",
    "<br />Standard Review: Drug approval within 10 months.\n",
    "<br />Priority Review: Drug approval within 6 months.\n",
    "\n",
    "**Reasons for denying approval**\n",
    "<br />Unexpected safety issues, manufacturing issues or a failure to prove a drugâ€™s effectiveness.\n",
    "\n",
    "**The drug approval process**\n",
    "<br />Basic safety of drug is tested through chemical tests and animal tests.\n",
    "<br />Clinical trials consist of 3 phases.\n",
    "\n",
    "1. Phase 1\n",
    "    - Length: Several months\n",
    "    - Participants: 20 to 100 healhy volunteers / people with disease\n",
    "    - Selectivity: 70% pass\n",
    "    - Intention: Test how drug interacts with human body, adjusting human dosage based on animal data, find out how much body can tolerate and acute side effects, how to best administer the drug to limit risks and maximize benefits\n",
    "    \n",
    "    \n",
    "2. Phase 2\n",
    "    - Length: Several months to 2 years \n",
    "    - Participants: Several hundred people with disease\n",
    "    - Selectivity: 33% pass\n",
    "    - Intention: Establish research questions, research methods, and design P3 research protocols, provide additional safety data. Note: this study is still not large enough to show whether drug will help treat the target condition\n",
    "\n",
    "\n",
    "3. Phase 3\n",
    "    - Length: 1 to 4 years\n",
    "    - Participants: 300 to 3000\n",
    "    - Selectivity: 25-30% pass\n",
    "    - Intention: Test if it offers a treatment benefit to a specific population, \"Pivotal studies\", provides most safety data - reveals long term or rare side effects\n",
    "\n",
    "Passing of phase 3 means FDA approval is given and the drug is released to the market.\n",
    "\n",
    "4. Phase 4\n",
    "    - Several thousand volunteers\n",
    "    - Carried out once drug approved by FDA in _Post Market Safety Monitoring_\n",
    "\n",
    "**Notes**\n",
    "<br />Medical Devices have Class I, II, III based on how invasive they are - Pharmaceutical companies are allowed to announce devices before approval process.\n",
    "\n",
    "\n",
    "As can be seen, the most pivotal stage of the FDA approval process is phase 3, as this approval is followed by bringing the drugs to market and is tje most selective and long process."
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "id": "9d42806d",
   "metadata": {},
   "source": [
    "## Method\n",
    "\n",
    "Testing this hypothesis can be broken into the following steps:\n",
    "\n",
    "1. Collecting small cap pharmaceutical company tickers: find all indexed pharmaceutical stocks, filter by market cap\n",
    "2. Collect each stock's FDA drug approval history\n",
    "3. Data Cleaning\n",
    "4. Collect price change data: 1mo at 1hr intervals of stock data following news\n",
    "5. Analysis: Compare stock performance following news vs. performance of same time frame drawing from a random sample of ticker price history\n",
    "\n",
    "### Importing Libraries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "id": "f5234370",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package punkt to\n",
      "[nltk_data]     /Users/cyprianzander/nltk_data...\n",
      "[nltk_data]   Package punkt is already up-to-date!\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 101,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import yfinance as yf\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "from tqdm import tqdm\n",
    "import matplotlib.pyplot as plt\n",
    "%matplotlib inline\n",
    "from datetime import datetime\n",
    "import nltk\n",
    "nltk.download('punkt')\n",
    "\n",
    "from IPython.core.interactiveshell import InteractiveShell\n",
    "InteractiveShell.ast_node_interactivity = \"all\""
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "id": "fedf5379",
   "metadata": {},
   "source": [
    "### 1. Collecting small cap pharmaceutical company tickers\n",
    "\n",
    "Nasdaq's stock screener (https://www.nasdaq.com/market-activity/stocks/screener) enables filtering of stocks by exchange, market cap, analyst rating, sector, region, and country. We collect tickers from NYSE, NASDAQ, and AMEX by filtering out stocks with market cap > $10B, as these stocks would no longer be considered \"small cap\", thus falling outside of the parameters of our hypothesis and searching by sector: \"Healthcare\".\n",
    "\n",
    "The prepared CSV file now contains 1200 observations, but these also need to be filtered by industry (\"Biotechnology: Pharmaceutical Preparations\"), as this industry focusses on pharmaceutical drug preparation."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "6db0b241",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Symbol</th>\n",
       "      <th>Name</th>\n",
       "      <th>Last Sale</th>\n",
       "      <th>Net Change</th>\n",
       "      <th>% Change</th>\n",
       "      <th>Market Cap</th>\n",
       "      <th>Country</th>\n",
       "      <th>IPO Year</th>\n",
       "      <th>Volume</th>\n",
       "      <th>Sector</th>\n",
       "      <th>Industry</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>AADI</td>\n",
       "      <td>Aadi Bioscience Inc. Common Stock</td>\n",
       "      <td>$7.94</td>\n",
       "      <td>0.1600</td>\n",
       "      <td>2.057%</td>\n",
       "      <td>1.940297e+08</td>\n",
       "      <td>United States</td>\n",
       "      <td>NaN</td>\n",
       "      <td>46995</td>\n",
       "      <td>Health Care</td>\n",
       "      <td>Biotechnology: Pharmaceutical Preparations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>ABEO</td>\n",
       "      <td>Abeona Therapeutics Inc. Common Stock</td>\n",
       "      <td>$3.32</td>\n",
       "      <td>0.0600</td>\n",
       "      <td>1.84%</td>\n",
       "      <td>5.919898e+07</td>\n",
       "      <td>United States</td>\n",
       "      <td>NaN</td>\n",
       "      <td>104342</td>\n",
       "      <td>Health Care</td>\n",
       "      <td>Biotechnology: Pharmaceutical Preparations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>ABOS</td>\n",
       "      <td>Acumen Pharmaceuticals Inc. Common Stock</td>\n",
       "      <td>$5.1675</td>\n",
       "      <td>1.1175</td>\n",
       "      <td>27.593%</td>\n",
       "      <td>2.119970e+08</td>\n",
       "      <td>United States</td>\n",
       "      <td>2021.0</td>\n",
       "      <td>1167028</td>\n",
       "      <td>Health Care</td>\n",
       "      <td>Biotechnology: Pharmaceutical Preparations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>ABSI</td>\n",
       "      <td>Absci Corporation Common Stock</td>\n",
       "      <td>$1.40</td>\n",
       "      <td>0.0900</td>\n",
       "      <td>6.87%</td>\n",
       "      <td>1.293529e+08</td>\n",
       "      <td>United States</td>\n",
       "      <td>2021.0</td>\n",
       "      <td>519172</td>\n",
       "      <td>Health Care</td>\n",
       "      <td>Biotechnology: Pharmaceutical Preparations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>ABVC</td>\n",
       "      <td>ABVC BioPharma Inc. Common Stock</td>\n",
       "      <td>$0.80</td>\n",
       "      <td>0.0500</td>\n",
       "      <td>6.667%</td>\n",
       "      <td>2.646459e+07</td>\n",
       "      <td>United States</td>\n",
       "      <td>NaN</td>\n",
       "      <td>36071</td>\n",
       "      <td>Health Care</td>\n",
       "      <td>Biotechnology: Pharmaceutical Preparations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>ACAD</td>\n",
       "      <td>ACADIA Pharmaceuticals Inc. Common Stock</td>\n",
       "      <td>$21.97</td>\n",
       "      <td>0.4200</td>\n",
       "      <td>1.949%</td>\n",
       "      <td>3.564197e+09</td>\n",
       "      <td>United States</td>\n",
       "      <td>1985.0</td>\n",
       "      <td>709500</td>\n",
       "      <td>Health Care</td>\n",
       "      <td>Biotechnology: Pharmaceutical Preparations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>ACER</td>\n",
       "      <td>Acer Therapeutics Inc. Common Stock (DE)</td>\n",
       "      <td>$0.7625</td>\n",
       "      <td>0.0065</td>\n",
       "      <td>0.86%</td>\n",
       "      <td>1.785892e+07</td>\n",
       "      <td>United States</td>\n",
       "      <td>NaN</td>\n",
       "      <td>224730</td>\n",
       "      <td>Health Care</td>\n",
       "      <td>Biotechnology: Pharmaceutical Preparations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>ACET</td>\n",
       "      <td>Adicet Bio Inc. Common Stock</td>\n",
       "      <td>$6.45</td>\n",
       "      <td>0.0700</td>\n",
       "      <td>1.097%</td>\n",
       "      <td>1.263544e+08</td>\n",
       "      <td>United States</td>\n",
       "      <td>2018.0</td>\n",
       "      <td>109847</td>\n",
       "      <td>Health Care</td>\n",
       "      <td>Biotechnology: Pharmaceutical Preparations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>ACIU</td>\n",
       "      <td>AC Immune SA Common Stock</td>\n",
       "      <td>$2.07</td>\n",
       "      <td>0.0100</td>\n",
       "      <td>0.485%</td>\n",
       "      <td>1.730942e+08</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>2016.0</td>\n",
       "      <td>158640</td>\n",
       "      <td>Health Care</td>\n",
       "      <td>Biotechnology: Pharmaceutical Preparations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>ACLX</td>\n",
       "      <td>Arcellx Inc. Common Stock</td>\n",
       "      <td>$44.01</td>\n",
       "      <td>0.7500</td>\n",
       "      <td>1.734%</td>\n",
       "      <td>2.105455e+09</td>\n",
       "      <td>United States</td>\n",
       "      <td>2022.0</td>\n",
       "      <td>385064</td>\n",
       "      <td>Health Care</td>\n",
       "      <td>Biotechnology: Pharmaceutical Preparations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>ACRX</td>\n",
       "      <td>AcelRx Pharmaceuticals Inc. Common Stock</td>\n",
       "      <td>$0.6485</td>\n",
       "      <td>0.0286</td>\n",
       "      <td>4.614%</td>\n",
       "      <td>7.080616e+06</td>\n",
       "      <td>United States</td>\n",
       "      <td>2011.0</td>\n",
       "      <td>184588</td>\n",
       "      <td>Health Care</td>\n",
       "      <td>Biotechnology: Pharmaceutical Preparations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>ACST</td>\n",
       "      <td>Acasti Pharma Inc. Class A Common Stock</td>\n",
       "      <td>$0.4499</td>\n",
       "      <td>0.0100</td>\n",
       "      <td>2.273%</td>\n",
       "      <td>2.007131e+07</td>\n",
       "      <td>Canada</td>\n",
       "      <td>NaN</td>\n",
       "      <td>33786</td>\n",
       "      <td>Health Care</td>\n",
       "      <td>Biotechnology: Pharmaceutical Preparations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>ACXP</td>\n",
       "      <td>Acurx Pharmaceuticals Inc. Common Stock</td>\n",
       "      <td>$2.9927</td>\n",
       "      <td>0.0627</td>\n",
       "      <td>2.14%</td>\n",
       "      <td>3.482244e+07</td>\n",
       "      <td>United States</td>\n",
       "      <td>2021.0</td>\n",
       "      <td>15589</td>\n",
       "      <td>Health Care</td>\n",
       "      <td>Biotechnology: Pharmaceutical Preparations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>ADAG</td>\n",
       "      <td>Adagene Inc. American Depositary Shares</td>\n",
       "      <td>$1.34</td>\n",
       "      <td>0.0500</td>\n",
       "      <td>3.876%</td>\n",
       "      <td>5.795844e+07</td>\n",
       "      <td>China</td>\n",
       "      <td>2021.0</td>\n",
       "      <td>14830</td>\n",
       "      <td>Health Care</td>\n",
       "      <td>Biotechnology: Pharmaceutical Preparations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>ADCT</td>\n",
       "      <td>ADC Therapeutics SA Common Shares</td>\n",
       "      <td>$1.98</td>\n",
       "      <td>0.0400</td>\n",
       "      <td>2.062%</td>\n",
       "      <td>1.596722e+08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>229911</td>\n",
       "      <td>Health Care</td>\n",
       "      <td>Biotechnology: Pharmaceutical Preparations</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Symbol                                      Name Last Sale  Net Change  \\\n",
       "0    AADI         Aadi Bioscience Inc. Common Stock     $7.94      0.1600   \n",
       "3    ABEO     Abeona Therapeutics Inc. Common Stock     $3.32      0.0600   \n",
       "5    ABOS  Acumen Pharmaceuticals Inc. Common Stock   $5.1675      1.1175   \n",
       "6    ABSI            Absci Corporation Common Stock     $1.40      0.0900   \n",
       "8    ABVC          ABVC BioPharma Inc. Common Stock     $0.80      0.0500   \n",
       "9    ACAD  ACADIA Pharmaceuticals Inc. Common Stock    $21.97      0.4200   \n",
       "11   ACER  Acer Therapeutics Inc. Common Stock (DE)   $0.7625      0.0065   \n",
       "12   ACET             Adicet Bio Inc. Common Stock      $6.45      0.0700   \n",
       "17   ACIU                 AC Immune SA Common Stock     $2.07      0.0100   \n",
       "18   ACLX                 Arcellx Inc. Common Stock    $44.01      0.7500   \n",
       "22   ACRX  AcelRx Pharmaceuticals Inc. Common Stock   $0.6485      0.0286   \n",
       "23   ACST   Acasti Pharma Inc. Class A Common Stock   $0.4499      0.0100   \n",
       "24   ACXP   Acurx Pharmaceuticals Inc. Common Stock   $2.9927      0.0627   \n",
       "25   ADAG   Adagene Inc. American Depositary Shares     $1.34      0.0500   \n",
       "27   ADCT         ADC Therapeutics SA Common Shares     $1.98      0.0400   \n",
       "\n",
       "   % Change    Market Cap        Country  IPO Year   Volume       Sector  \\\n",
       "0    2.057%  1.940297e+08  United States       NaN    46995  Health Care   \n",
       "3     1.84%  5.919898e+07  United States       NaN   104342  Health Care   \n",
       "5   27.593%  2.119970e+08  United States    2021.0  1167028  Health Care   \n",
       "6     6.87%  1.293529e+08  United States    2021.0   519172  Health Care   \n",
       "8    6.667%  2.646459e+07  United States       NaN    36071  Health Care   \n",
       "9    1.949%  3.564197e+09  United States    1985.0   709500  Health Care   \n",
       "11    0.86%  1.785892e+07  United States       NaN   224730  Health Care   \n",
       "12   1.097%  1.263544e+08  United States    2018.0   109847  Health Care   \n",
       "17   0.485%  1.730942e+08    Switzerland    2016.0   158640  Health Care   \n",
       "18   1.734%  2.105455e+09  United States    2022.0   385064  Health Care   \n",
       "22   4.614%  7.080616e+06  United States    2011.0   184588  Health Care   \n",
       "23   2.273%  2.007131e+07         Canada       NaN    33786  Health Care   \n",
       "24    2.14%  3.482244e+07  United States    2021.0    15589  Health Care   \n",
       "25   3.876%  5.795844e+07          China    2021.0    14830  Health Care   \n",
       "27   2.062%  1.596722e+08            NaN    2020.0   229911  Health Care   \n",
       "\n",
       "                                      Industry  \n",
       "0   Biotechnology: Pharmaceutical Preparations  \n",
       "3   Biotechnology: Pharmaceutical Preparations  \n",
       "5   Biotechnology: Pharmaceutical Preparations  \n",
       "6   Biotechnology: Pharmaceutical Preparations  \n",
       "8   Biotechnology: Pharmaceutical Preparations  \n",
       "9   Biotechnology: Pharmaceutical Preparations  \n",
       "11  Biotechnology: Pharmaceutical Preparations  \n",
       "12  Biotechnology: Pharmaceutical Preparations  \n",
       "17  Biotechnology: Pharmaceutical Preparations  \n",
       "18  Biotechnology: Pharmaceutical Preparations  \n",
       "22  Biotechnology: Pharmaceutical Preparations  \n",
       "23  Biotechnology: Pharmaceutical Preparations  \n",
       "24  Biotechnology: Pharmaceutical Preparations  \n",
       "25  Biotechnology: Pharmaceutical Preparations  \n",
       "27  Biotechnology: Pharmaceutical Preparations  "
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "pharmaceutical_preparations contains 619 tickers.\n"
     ]
    }
   ],
   "source": [
    "healthcare_stocks = pd.read_csv(\"nasdaq_screener_1683316923031.csv\")\n",
    "\n",
    "pharmaceutical_preparations = healthcare_stocks.loc[healthcare_stocks[\"Industry\"] == \"Biotechnology: Pharmaceutical Preparations\"] # Filter by Industry\n",
    "pharmaceutical_preparations.head(15)\n",
    "print(\"pharmaceutical_preparations contains\", len(pharmaceutical_preparations.index), \"tickers.\")\n"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "id": "4fd29ef8",
   "metadata": {},
   "source": [
    "\n",
    "### 2. Collect each stock's FDA drug approval history\n",
    "\n",
    "Having collected all 619 small-cap pharmaceutical preparation stock tickers, the data to correlate these stocks by is their FDA approval history. \n",
    "\n",
    "From the FDA website, we use the past 10 years of drug approval data (see https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases) and match these with our ticker symbols and name collected previously. This requires some data cleaning, as the FDA data has company name abbreviations that do not match the company symbol or name from pharmaceutical_preparations.\n",
    "\n",
    "Data can only be collected on a by-month basis, thus the data loading is a bit more sophisticated.\n",
    "\n",
    "Notable about this data is that it does not include phase 1, phase 2, and phase 3 distinctions, but rather only phase 3 approved drugs. An extension to this project could be finding / generating a more rigorous database that also tracks phase 1 and phase 2 approvals."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "id": "4aba22d2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Approval Date</th>\n",
       "      <th>Drug Name</th>\n",
       "      <th>Submission</th>\n",
       "      <th>Active Ingredients</th>\n",
       "      <th>Company</th>\n",
       "      <th>Submission Classification *</th>\n",
       "      <th>Submission Status</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>01/02/2018</td>\n",
       "      <td>EXCEDRIN (MIGRAINE RELIEF)NDA   #020802</td>\n",
       "      <td>SUPPL-32</td>\n",
       "      <td>ACETAMINOPHEN; ASPIRIN; CAFFEINE</td>\n",
       "      <td>GLAXOSMITHKLINE CONS</td>\n",
       "      <td>Labeling</td>\n",
       "      <td>Approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>01/02/2018</td>\n",
       "      <td>DOXYCYCLINE HYCLATEANDA  #062031</td>\n",
       "      <td>SUPPL-79</td>\n",
       "      <td>DOXYCYCLINE HYCLATE</td>\n",
       "      <td>ACTAVIS LABS FL INC</td>\n",
       "      <td>Labeling</td>\n",
       "      <td>Approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>01/02/2018</td>\n",
       "      <td>DOXYCYCLINE HYCLATEANDA  #062031</td>\n",
       "      <td>SUPPL-80</td>\n",
       "      <td>DOXYCYCLINE HYCLATE</td>\n",
       "      <td>ACTAVIS LABS FL INC</td>\n",
       "      <td>Labeling</td>\n",
       "      <td>Approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>01/02/2018</td>\n",
       "      <td>DOXYCYCLINE HYCLATEANDA  #062421</td>\n",
       "      <td>SUPPL-62</td>\n",
       "      <td>DOXYCYCLINE HYCLATE</td>\n",
       "      <td>ACTAVIS LABS FL INC</td>\n",
       "      <td>Labeling</td>\n",
       "      <td>Approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>01/02/2018</td>\n",
       "      <td>DOXYCYCLINE HYCLATEANDA  #062421</td>\n",
       "      <td>SUPPL-67</td>\n",
       "      <td>DOXYCYCLINE HYCLATE</td>\n",
       "      <td>ACTAVIS LABS FL INC</td>\n",
       "      <td>Labeling</td>\n",
       "      <td>Approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>01/02/2018</td>\n",
       "      <td>DOXYCYCLINE HYCLATEANDA  #062421</td>\n",
       "      <td>SUPPL-68</td>\n",
       "      <td>DOXYCYCLINE HYCLATE</td>\n",
       "      <td>ACTAVIS LABS FL INC</td>\n",
       "      <td>Labeling</td>\n",
       "      <td>Approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>01/02/2018</td>\n",
       "      <td>INVOKAMET XRNDA   #205879</td>\n",
       "      <td>SUPPL-2</td>\n",
       "      <td>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE</td>\n",
       "      <td>JANSSEN PHARMS</td>\n",
       "      <td>Efficacy</td>\n",
       "      <td>Approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>01/03/2018</td>\n",
       "      <td>TROKENDI XRNDA   #201635</td>\n",
       "      <td>SUPPL-18</td>\n",
       "      <td>TOPIRAMATE</td>\n",
       "      <td>SUPERNUS PHARMS</td>\n",
       "      <td>Labeling</td>\n",
       "      <td>Approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>01/04/2018</td>\n",
       "      <td>PARNATENDA   #012342</td>\n",
       "      <td>SUPPL-64</td>\n",
       "      <td>TRANYLCYPROMINE SULFATE</td>\n",
       "      <td>CONCORDIA</td>\n",
       "      <td>Labeling</td>\n",
       "      <td>Approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>01/04/2018</td>\n",
       "      <td>NOXAFILNDA   #022003</td>\n",
       "      <td>SUPPL-22</td>\n",
       "      <td>POSACONAZOLE</td>\n",
       "      <td>SCHERING</td>\n",
       "      <td>Labeling</td>\n",
       "      <td>Approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>01/04/2018</td>\n",
       "      <td>PROLIABLA   #125320</td>\n",
       "      <td>SUPPL-182</td>\n",
       "      <td>DENOSUMAB</td>\n",
       "      <td>AMGEN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>01/04/2018</td>\n",
       "      <td>XGEVABLA   #125320</td>\n",
       "      <td>SUPPL-182</td>\n",
       "      <td>DENOSUMAB</td>\n",
       "      <td>AMGEN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>01/04/2018</td>\n",
       "      <td>DOCETAXELANDA  #204193</td>\n",
       "      <td>SUPPL-4</td>\n",
       "      <td>DOCETAXEL</td>\n",
       "      <td>DR REDDYS</td>\n",
       "      <td>Labeling</td>\n",
       "      <td>Approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>01/04/2018</td>\n",
       "      <td>NOXAFILNDA   #205053</td>\n",
       "      <td>SUPPL-6</td>\n",
       "      <td>POSACONAZOLE</td>\n",
       "      <td>MERCK SHARP DOHME</td>\n",
       "      <td>Labeling</td>\n",
       "      <td>Approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>01/04/2018</td>\n",
       "      <td>NOXAFILNDA   #205596</td>\n",
       "      <td>SUPPL-5</td>\n",
       "      <td>POSACONAZOLE</td>\n",
       "      <td>MERCK SHARP DOHME</td>\n",
       "      <td>Labeling</td>\n",
       "      <td>Approval</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Approval Date                                Drug Name Submission  \\\n",
       "0     01/02/2018  EXCEDRIN (MIGRAINE RELIEF)NDA   #020802   SUPPL-32   \n",
       "1     01/02/2018         DOXYCYCLINE HYCLATEANDA  #062031   SUPPL-79   \n",
       "2     01/02/2018         DOXYCYCLINE HYCLATEANDA  #062031   SUPPL-80   \n",
       "3     01/02/2018         DOXYCYCLINE HYCLATEANDA  #062421   SUPPL-62   \n",
       "4     01/02/2018         DOXYCYCLINE HYCLATEANDA  #062421   SUPPL-67   \n",
       "5     01/02/2018         DOXYCYCLINE HYCLATEANDA  #062421   SUPPL-68   \n",
       "6     01/02/2018                INVOKAMET XRNDA   #205879    SUPPL-2   \n",
       "7     01/03/2018                 TROKENDI XRNDA   #201635   SUPPL-18   \n",
       "8     01/04/2018                     PARNATENDA   #012342   SUPPL-64   \n",
       "9     01/04/2018                     NOXAFILNDA   #022003   SUPPL-22   \n",
       "10    01/04/2018                      PROLIABLA   #125320  SUPPL-182   \n",
       "11    01/04/2018                       XGEVABLA   #125320  SUPPL-182   \n",
       "12    01/04/2018                   DOCETAXELANDA  #204193    SUPPL-4   \n",
       "13    01/04/2018                     NOXAFILNDA   #205053    SUPPL-6   \n",
       "14    01/04/2018                     NOXAFILNDA   #205596    SUPPL-5   \n",
       "\n",
       "                        Active Ingredients               Company  \\\n",
       "0         ACETAMINOPHEN; ASPIRIN; CAFFEINE  GLAXOSMITHKLINE CONS   \n",
       "1                      DOXYCYCLINE HYCLATE   ACTAVIS LABS FL INC   \n",
       "2                      DOXYCYCLINE HYCLATE   ACTAVIS LABS FL INC   \n",
       "3                      DOXYCYCLINE HYCLATE   ACTAVIS LABS FL INC   \n",
       "4                      DOXYCYCLINE HYCLATE   ACTAVIS LABS FL INC   \n",
       "5                      DOXYCYCLINE HYCLATE   ACTAVIS LABS FL INC   \n",
       "6   CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE        JANSSEN PHARMS   \n",
       "7                               TOPIRAMATE       SUPERNUS PHARMS   \n",
       "8                  TRANYLCYPROMINE SULFATE             CONCORDIA   \n",
       "9                             POSACONAZOLE              SCHERING   \n",
       "10                               DENOSUMAB                 AMGEN   \n",
       "11                               DENOSUMAB                 AMGEN   \n",
       "12                               DOCETAXEL             DR REDDYS   \n",
       "13                            POSACONAZOLE     MERCK SHARP DOHME   \n",
       "14                            POSACONAZOLE     MERCK SHARP DOHME   \n",
       "\n",
       "   Submission Classification * Submission Status  \n",
       "0                     Labeling          Approval  \n",
       "1                     Labeling          Approval  \n",
       "2                     Labeling          Approval  \n",
       "3                     Labeling          Approval  \n",
       "4                     Labeling          Approval  \n",
       "5                     Labeling          Approval  \n",
       "6                     Efficacy          Approval  \n",
       "7                     Labeling          Approval  \n",
       "8                     Labeling          Approval  \n",
       "9                     Labeling          Approval  \n",
       "10                         NaN          Approval  \n",
       "11                         NaN          Approval  \n",
       "12                    Labeling          Approval  \n",
       "13                    Labeling          Approval  \n",
       "14                    Labeling          Approval  "
      ]
     },
     "execution_count": 97,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "all_FDA_approvals contains 24419 drug approvals.\n"
     ]
    }
   ],
   "source": [
    "start_year_incl = 18 # 2022\n",
    "end_year_excl = 23 # 2023\n",
    "\n",
    "all_FDA_approvals = pd.DataFrame()\n",
    "\n",
    "for i in range(start_year_incl, end_year_excl): # year\n",
    "    for j in range(1, 13): # month\n",
    "        current_month_FDA = pd.read_csv(\"./FDA_approvals/%02d%02d.csv\" % (j,i,)) #gather data\n",
    "        all_FDA_approvals = pd.concat([all_FDA_approvals, current_month_FDA], axis=0)\n",
    "\n",
    "all_FDA_approvals.head(15)\n",
    "print(\"all_FDA_approvals contains\", len(all_FDA_approvals.index), \"drug approvals.\")"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "id": "36f7a442",
   "metadata": {},
   "source": [
    "### 3. Data cleaning and preparation\n",
    "\n",
    "We take the following data cleaning steps:\n",
    "\n",
    "1. Lowercasing entries\n",
    "2. Tokenizing company name\n",
    "3. Removing unnecessary columns\n",
    "4. Removing common company phrases to avoid mismatch\n",
    "5. Matching stock symbol & name from `pharmaceutical_preparations` with events from `all_FDA_approvals`"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/qq/q9njxf715r5_sygj6w0kh68h0000gn/T/ipykernel_58987/3105478115.py:26: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  FDA_approvals_short[\"Company Token\"] = FDA_approvals_short[\"Company Token\"].apply(lambda x: [item for item in x if item not in common_words_list])\n",
      "/var/folders/qq/q9njxf715r5_sygj6w0kh68h0000gn/T/ipykernel_58987/3105478115.py:27: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  pharma_symbols[\"Company Token\"] = pharma_symbols[\"Company Token\"].apply(lambda x: [item for item in x if item not in common_words_list])\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Approval Date</th>\n",
       "      <th>Company Token</th>\n",
       "      <th>Submission</th>\n",
       "      <th>Active Ingredients</th>\n",
       "      <th>Submission Classification *</th>\n",
       "      <th>Submission Status</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>01/02/2018</td>\n",
       "      <td>[glaxosmithkline, cons]</td>\n",
       "      <td>suppl-32</td>\n",
       "      <td>acetaminophen; aspirin; caffeine</td>\n",
       "      <td>labeling</td>\n",
       "      <td>approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>01/02/2018</td>\n",
       "      <td>[actavis, fl]</td>\n",
       "      <td>suppl-79</td>\n",
       "      <td>doxycycline hyclate</td>\n",
       "      <td>labeling</td>\n",
       "      <td>approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>01/02/2018</td>\n",
       "      <td>[actavis, fl]</td>\n",
       "      <td>suppl-80</td>\n",
       "      <td>doxycycline hyclate</td>\n",
       "      <td>labeling</td>\n",
       "      <td>approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>01/02/2018</td>\n",
       "      <td>[actavis, fl]</td>\n",
       "      <td>suppl-62</td>\n",
       "      <td>doxycycline hyclate</td>\n",
       "      <td>labeling</td>\n",
       "      <td>approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>01/02/2018</td>\n",
       "      <td>[actavis, fl]</td>\n",
       "      <td>suppl-67</td>\n",
       "      <td>doxycycline hyclate</td>\n",
       "      <td>labeling</td>\n",
       "      <td>approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>01/02/2018</td>\n",
       "      <td>[actavis, fl]</td>\n",
       "      <td>suppl-68</td>\n",
       "      <td>doxycycline hyclate</td>\n",
       "      <td>labeling</td>\n",
       "      <td>approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>01/02/2018</td>\n",
       "      <td>[janssen]</td>\n",
       "      <td>suppl-2</td>\n",
       "      <td>canagliflozin; metformin hydrochloride</td>\n",
       "      <td>efficacy</td>\n",
       "      <td>approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>01/03/2018</td>\n",
       "      <td>[supernus]</td>\n",
       "      <td>suppl-18</td>\n",
       "      <td>topiramate</td>\n",
       "      <td>labeling</td>\n",
       "      <td>approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>01/04/2018</td>\n",
       "      <td>[concordia]</td>\n",
       "      <td>suppl-64</td>\n",
       "      <td>tranylcypromine sulfate</td>\n",
       "      <td>labeling</td>\n",
       "      <td>approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>01/04/2018</td>\n",
       "      <td>[schering]</td>\n",
       "      <td>suppl-22</td>\n",
       "      <td>posaconazole</td>\n",
       "      <td>labeling</td>\n",
       "      <td>approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>01/04/2018</td>\n",
       "      <td>[amgen]</td>\n",
       "      <td>suppl-182</td>\n",
       "      <td>denosumab</td>\n",
       "      <td>NaN</td>\n",
       "      <td>approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>01/04/2018</td>\n",
       "      <td>[amgen]</td>\n",
       "      <td>suppl-182</td>\n",
       "      <td>denosumab</td>\n",
       "      <td>NaN</td>\n",
       "      <td>approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>01/04/2018</td>\n",
       "      <td>[reddys]</td>\n",
       "      <td>suppl-4</td>\n",
       "      <td>docetaxel</td>\n",
       "      <td>labeling</td>\n",
       "      <td>approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>01/04/2018</td>\n",
       "      <td>[merck, dohme]</td>\n",
       "      <td>suppl-6</td>\n",
       "      <td>posaconazole</td>\n",
       "      <td>labeling</td>\n",
       "      <td>approval</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>01/04/2018</td>\n",
       "      <td>[merck, dohme]</td>\n",
       "      <td>suppl-5</td>\n",
       "      <td>posaconazole</td>\n",
       "      <td>labeling</td>\n",
       "      <td>approval</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Approval Date            Company Token Submission  \\\n",
       "0     01/02/2018  [glaxosmithkline, cons]   suppl-32   \n",
       "1     01/02/2018            [actavis, fl]   suppl-79   \n",
       "2     01/02/2018            [actavis, fl]   suppl-80   \n",
       "3     01/02/2018            [actavis, fl]   suppl-62   \n",
       "4     01/02/2018            [actavis, fl]   suppl-67   \n",
       "5     01/02/2018            [actavis, fl]   suppl-68   \n",
       "6     01/02/2018                [janssen]    suppl-2   \n",
       "7     01/03/2018               [supernus]   suppl-18   \n",
       "8     01/04/2018              [concordia]   suppl-64   \n",
       "9     01/04/2018               [schering]   suppl-22   \n",
       "10    01/04/2018                  [amgen]  suppl-182   \n",
       "11    01/04/2018                  [amgen]  suppl-182   \n",
       "12    01/04/2018                 [reddys]    suppl-4   \n",
       "13    01/04/2018           [merck, dohme]    suppl-6   \n",
       "14    01/04/2018           [merck, dohme]    suppl-5   \n",
       "\n",
       "                        Active Ingredients Submission Classification *  \\\n",
       "0         acetaminophen; aspirin; caffeine                    labeling   \n",
       "1                      doxycycline hyclate                    labeling   \n",
       "2                      doxycycline hyclate                    labeling   \n",
       "3                      doxycycline hyclate                    labeling   \n",
       "4                      doxycycline hyclate                    labeling   \n",
       "5                      doxycycline hyclate                    labeling   \n",
       "6   canagliflozin; metformin hydrochloride                    efficacy   \n",
       "7                               topiramate                    labeling   \n",
       "8                  tranylcypromine sulfate                    labeling   \n",
       "9                             posaconazole                    labeling   \n",
       "10                               denosumab                         NaN   \n",
       "11                               denosumab                         NaN   \n",
       "12                               docetaxel                    labeling   \n",
       "13                            posaconazole                    labeling   \n",
       "14                            posaconazole                    labeling   \n",
       "\n",
       "   Submission Status  \n",
       "0           approval  \n",
       "1           approval  \n",
       "2           approval  \n",
       "3           approval  \n",
       "4           approval  \n",
       "5           approval  \n",
       "6           approval  \n",
       "7           approval  \n",
       "8           approval  \n",
       "9           approval  \n",
       "10          approval  \n",
       "11          approval  \n",
       "12          approval  \n",
       "13          approval  \n",
       "14          approval  "
      ]
     },
     "execution_count": 98,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Symbol</th>\n",
       "      <th>Name</th>\n",
       "      <th>Company Token</th>\n",
       "      <th>Market Cap</th>\n",
       "      <th>Country</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>aadi</td>\n",
       "      <td>aadi bioscience inc. common stock</td>\n",
       "      <td>[aadi]</td>\n",
       "      <td>1.940297e+08</td>\n",
       "      <td>united states</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>abeo</td>\n",
       "      <td>abeona therapeutics inc. common stock</td>\n",
       "      <td>[abeona]</td>\n",
       "      <td>5.919898e+07</td>\n",
       "      <td>united states</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>abos</td>\n",
       "      <td>acumen pharmaceuticals inc. common stock</td>\n",
       "      <td>[acumen]</td>\n",
       "      <td>2.119970e+08</td>\n",
       "      <td>united states</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>absi</td>\n",
       "      <td>absci corporation common stock</td>\n",
       "      <td>[absci]</td>\n",
       "      <td>1.293529e+08</td>\n",
       "      <td>united states</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>abvc</td>\n",
       "      <td>abvc biopharma inc. common stock</td>\n",
       "      <td>[abvc]</td>\n",
       "      <td>2.646459e+07</td>\n",
       "      <td>united states</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>acad</td>\n",
       "      <td>acadia pharmaceuticals inc. common stock</td>\n",
       "      <td>[acadia]</td>\n",
       "      <td>3.564197e+09</td>\n",
       "      <td>united states</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>acer</td>\n",
       "      <td>acer therapeutics inc. common stock (de)</td>\n",
       "      <td>[acer]</td>\n",
       "      <td>1.785892e+07</td>\n",
       "      <td>united states</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>acet</td>\n",
       "      <td>adicet bio inc. common stock</td>\n",
       "      <td>[adicet]</td>\n",
       "      <td>1.263544e+08</td>\n",
       "      <td>united states</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>aciu</td>\n",
       "      <td>ac immune sa common stock</td>\n",
       "      <td>[ac]</td>\n",
       "      <td>1.730942e+08</td>\n",
       "      <td>switzerland</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>aclx</td>\n",
       "      <td>arcellx inc. common stock</td>\n",
       "      <td>[arcellx]</td>\n",
       "      <td>2.105455e+09</td>\n",
       "      <td>united states</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>acrx</td>\n",
       "      <td>acelrx pharmaceuticals inc. common stock</td>\n",
       "      <td>[acelrx]</td>\n",
       "      <td>7.080616e+06</td>\n",
       "      <td>united states</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>acst</td>\n",
       "      <td>acasti pharma inc. class a common stock</td>\n",
       "      <td>[acasti]</td>\n",
       "      <td>2.007131e+07</td>\n",
       "      <td>canada</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>acxp</td>\n",
       "      <td>acurx pharmaceuticals inc. common stock</td>\n",
       "      <td>[acurx]</td>\n",
       "      <td>3.482244e+07</td>\n",
       "      <td>united states</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>adag</td>\n",
       "      <td>adagene inc. american depositary shares</td>\n",
       "      <td>[adagene]</td>\n",
       "      <td>5.795844e+07</td>\n",
       "      <td>china</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>adct</td>\n",
       "      <td>adc therapeutics sa common shares</td>\n",
       "      <td>[adc]</td>\n",
       "      <td>1.596722e+08</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Symbol                                      Name Company Token  \\\n",
       "0    aadi         aadi bioscience inc. common stock        [aadi]   \n",
       "3    abeo     abeona therapeutics inc. common stock      [abeona]   \n",
       "5    abos  acumen pharmaceuticals inc. common stock      [acumen]   \n",
       "6    absi            absci corporation common stock       [absci]   \n",
       "8    abvc          abvc biopharma inc. common stock        [abvc]   \n",
       "9    acad  acadia pharmaceuticals inc. common stock      [acadia]   \n",
       "11   acer  acer therapeutics inc. common stock (de)        [acer]   \n",
       "12   acet             adicet bio inc. common stock       [adicet]   \n",
       "17   aciu                 ac immune sa common stock          [ac]   \n",
       "18   aclx                 arcellx inc. common stock     [arcellx]   \n",
       "22   acrx  acelrx pharmaceuticals inc. common stock      [acelrx]   \n",
       "23   acst   acasti pharma inc. class a common stock      [acasti]   \n",
       "24   acxp   acurx pharmaceuticals inc. common stock       [acurx]   \n",
       "25   adag   adagene inc. american depositary shares     [adagene]   \n",
       "27   adct         adc therapeutics sa common shares         [adc]   \n",
       "\n",
       "      Market Cap        Country  \n",
       "0   1.940297e+08  united states  \n",
       "3   5.919898e+07  united states  \n",
       "5   2.119970e+08  united states  \n",
       "6   1.293529e+08  united states  \n",
       "8   2.646459e+07  united states  \n",
       "9   3.564197e+09  united states  \n",
       "11  1.785892e+07  united states  \n",
       "12  1.263544e+08  united states  \n",
       "17  1.730942e+08    switzerland  \n",
       "18  2.105455e+09  united states  \n",
       "22  7.080616e+06  united states  \n",
       "23  2.007131e+07         canada  \n",
       "24  3.482244e+07  united states  \n",
       "25  5.795844e+07          china  \n",
       "27  1.596722e+08            NaN  "
      ]
     },
     "execution_count": 98,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#1\n",
    "all_FDA_approvals = all_FDA_approvals.applymap(lambda s: s.lower() if type(s) == str else s) # lowercase all data\n",
    "pharmaceutical_preparations = pharmaceutical_preparations.applymap(lambda s: s.lower() if type(s) == str else s) # lowercase all data\n",
    "\n",
    "#2\n",
    "all_FDA_approvals['Company Token'] = all_FDA_approvals.apply(lambda row: nltk.word_tokenize(row['Company']), axis=1) # tokenize company name for matching with pharmaceutical_preparations table\n",
    "pharmaceutical_preparations['Company Token'] = pharmaceutical_preparations.apply(lambda row: nltk.word_tokenize(row['Name']), axis=1) # same for pharmaceutical_preparations\n",
    "\n",
    "#3\n",
    "pharma_symbols = pharmaceutical_preparations[[\"Symbol\", \"Name\", \"Company Token\", \"Market Cap\", \"Country\"]]\n",
    "FDA_approvals_short = all_FDA_approvals[[\"Approval Date\", \"Company Token\", \"Submission\", \"Active Ingredients\", \"Submission Classification *\", \"Submission Status\"]] # remove unecessary columns\n",
    "\n",
    "#4\n",
    "common_words_list = [\"hlthcare\", \"inc\", \"pharms\", \"industries\", \"sciences\", \"pharm\", \"pharma\", \"ltd\", \"llc\", \"corp\", \"labs\", \"dr\", \"prods\", \"usa\", \"laboratories\", \\\n",
    "                    \"biopharma\", \"grp\", \"biotech\", \"us\", \"sciences\", \"health\", \"global\", \"branded\", \"pte\", \"co\", \"iii\", \"ii\", \"iv\", \"v\", \"vi\", \"sa\", \"sas\", \"pvt\", \"lp\" \\\n",
    "                    \"ab\", \"and\", \"speclts\", \"products\", \"sterile\", \"common\", \"stock\", \"inc\", \"bio\", \"biopharma\", \"therapeutics\", \"american\", \"technologies\", \"corp\", \"plc\", \\\n",
    "                    \"ordinary\", \"shares\", \"corporation\", \"pharmaceuticals\", \"dna\", \"incorporated\", \"biosciences\", \"warrant\", \"biotherapeutics\", \"health\", \"class\", \"a\", \\\n",
    "                    \"b\", \"shs\", \"ltd\", \"medical\", \"holdings\", \"medicines\", \"depositary\", \"limited\", \"antibodies\", \"sciences\", \"incorporated\", \"group\", \"research\", \"&\", \"co\", \\\n",
    "                    \"financial\", \"life\", \"holding\", \"series\", \"systems\", \"biopharm\", \"diabetes\", \"bioscience\", \"physical\", \"therapy\", \"ltd.\", \"llc.\", \"u.s.a.\", \"u.s.\", \"inc.\", \\\n",
    "                    \"(\", \")\", \"immune\", \"warrants\", \"oncology\", \"biomedica\", \"corp.\", \"n.v.\", \"delaware\", \"companies\", \"fusion\", \"share\", \"euro\", \"israel\", \"sponsored\", \\\n",
    "                    \"technology\", \"pharmaceutical\", \"de\", \"convertible\", \"preferred\", \"biopharmaceuticals\", \"medicine\", \"biosolutions\", \"animal\", 'cumulative', 'redeemable', \\\n",
    "                    'perpetual', \"co.\", \"lifesciences\", \"china\", \"ireland\", \"biotechnology\", \"immunopharma\", \"biotechnology\", \"immunotherapeutics\", \"lifesciences\", \"biomed\", \\\n",
    "                    \"company\", \"neurosciences\", \"biomediacal\", \"biomedical\", \"ag\", \"healthcare\", \"consumer\", \"precision\", \"canada\", \"international\", \"nv\", \"depository\", \"intl\", \\\n",
    "                    \"r\", \"d\", \"farmaceutica\", \"medcl\", \"therap\", \"theraps\", \"molecular\", \"womens\", \"solutions\", \"steriscience\", \"ny\", \"lp\", \"india\", \"uk\", \"humanwell\", \"medicare\" \\\n",
    "                    \"int\", \"critical\", \"sharp\", \"int\", \"kabi\", \"teva\", \",\", \"ventures\", \"injectables\", \"aps\", \"n.v\", \"s.a\", \"therapies\"] # filter company tokens by these common words\n",
    "FDA_approvals_short[\"Company Token\"] = FDA_approvals_short[\"Company Token\"].apply(lambda x: [item for item in x if item not in common_words_list])\n",
    "pharma_symbols[\"Company Token\"] = pharma_symbols[\"Company Token\"].apply(lambda x: [item for item in x if item not in common_words_list])\n",
    "\n",
    "\n",
    "FDA_approvals_short.head(15)\n",
    "pharma_symbols.head(15)\n",
    "\n",
    "FDA_approvals_short.to_csv('FDA_approvals_short.csv')\n",
    "pharma_symbols.to_csv('pharma_symbols.csv')"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "id": "bfa162b5",
   "metadata": {},
   "source": [
    "As can be seen, the data cleaning, especially with regards to cleaning company share names from the ticker dataframe to be merged with FDA's shortcut names, works very well.\n",
    "\n",
    "Information is compressed only to relevant analysis data and company name cleaning works very well because of pharmaceutical company's very distinct names, allowing for quite effective merging using just the first company token from both dataframes."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "id": "178d30a9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Approval Date</th>\n",
       "      <th>Company Token</th>\n",
       "      <th>Submission</th>\n",
       "      <th>Active Ingredients</th>\n",
       "      <th>Submission Classification *</th>\n",
       "      <th>Submission Status</th>\n",
       "      <th>Symbol</th>\n",
       "      <th>Name</th>\n",
       "      <th>Market Cap</th>\n",
       "      <th>Country</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>01/03/2018</td>\n",
       "      <td>supernus</td>\n",
       "      <td>suppl-18</td>\n",
       "      <td>topiramate</td>\n",
       "      <td>labeling</td>\n",
       "      <td>approval</td>\n",
       "      <td>supn</td>\n",
       "      <td>supernus pharmaceuticals inc. common stock</td>\n",
       "      <td>1.996176e+09</td>\n",
       "      <td>united states</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>12/13/2018</td>\n",
       "      <td>supernus</td>\n",
       "      <td>suppl-10</td>\n",
       "      <td>oxcarbazepine</td>\n",
       "      <td>efficacy</td>\n",
       "      <td>approval</td>\n",
       "      <td>supn</td>\n",
       "      <td>supernus pharmaceuticals inc. common stock</td>\n",
       "      <td>1.996176e+09</td>\n",
       "      <td>united states</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>02/21/2019</td>\n",
       "      <td>supernus</td>\n",
       "      <td>suppl-20</td>\n",
       "      <td>topiramate</td>\n",
       "      <td>labeling</td>\n",
       "      <td>approval</td>\n",
       "      <td>supn</td>\n",
       "      <td>supernus pharmaceuticals inc. common stock</td>\n",
       "      <td>1.996176e+09</td>\n",
       "      <td>united states</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>11/18/2020</td>\n",
       "      <td>supernus</td>\n",
       "      <td>suppl-25</td>\n",
       "      <td>topiramate</td>\n",
       "      <td>labeling</td>\n",
       "      <td>approval</td>\n",
       "      <td>supn</td>\n",
       "      <td>supernus pharmaceuticals inc. common stock</td>\n",
       "      <td>1.996176e+09</td>\n",
       "      <td>united states</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>04/02/2021</td>\n",
       "      <td>supernus</td>\n",
       "      <td>orig-1</td>\n",
       "      <td>viloxazine hydrochloride</td>\n",
       "      <td>type 1 - new molecular entity</td>\n",
       "      <td>approval</td>\n",
       "      <td>supn</td>\n",
       "      <td>supernus pharmaceuticals inc. common stock</td>\n",
       "      <td>1.996176e+09</td>\n",
       "      <td>united states</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  Approval Date Company Token Submission        Active Ingredients  \\\n",
       "0    01/03/2018      supernus   suppl-18                topiramate   \n",
       "1    12/13/2018      supernus   suppl-10             oxcarbazepine   \n",
       "2    02/21/2019      supernus   suppl-20                topiramate   \n",
       "3    11/18/2020      supernus   suppl-25                topiramate   \n",
       "4    04/02/2021      supernus     orig-1  viloxazine hydrochloride   \n",
       "\n",
       "     Submission Classification * Submission Status Symbol  \\\n",
       "0                       labeling          approval   supn   \n",
       "1                       efficacy          approval   supn   \n",
       "2                       labeling          approval   supn   \n",
       "3                       labeling          approval   supn   \n",
       "4  type 1 - new molecular entity          approval   supn   \n",
       "\n",
       "                                         Name    Market Cap        Country  \n",
       "0  supernus pharmaceuticals inc. common stock  1.996176e+09  united states  \n",
       "1  supernus pharmaceuticals inc. common stock  1.996176e+09  united states  \n",
       "2  supernus pharmaceuticals inc. common stock  1.996176e+09  united states  \n",
       "3  supernus pharmaceuticals inc. common stock  1.996176e+09  united states  \n",
       "4  supernus pharmaceuticals inc. common stock  1.996176e+09  united states  "
      ]
     },
     "execution_count": 99,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "symbols_FDA contains 1626 observations.\n"
     ]
    }
   ],
   "source": [
    "#5\n",
    "pharma_symbols = pharma_symbols[pharma_symbols['Company Token'].apply(lambda x: bool(x))] # remove empty company tokens\n",
    "pharma_symbols['Company Token'] = pharma_symbols['Company Token'].apply(lambda x: x[0]) # take the first element of company tokens\n",
    "pharma_symbols = pharma_symbols.reset_index(drop=True)\n",
    "pharma_symbols['Company Token'] = pharma_symbols['Company Token'].astype(str)\n",
    "\n",
    "FDA_approvals_short = FDA_approvals_short[FDA_approvals_short['Company Token'].apply(lambda x: bool(x))]\n",
    "FDA_approvals_short['Company Token'] = FDA_approvals_short['Company Token'].apply(lambda x: x[0])\n",
    "FDA_approvals_short = FDA_approvals_short.reset_index(drop=True)\n",
    "FDA_approvals_short['Company Token'] = FDA_approvals_short['Company Token'].astype(str)\n",
    "\n",
    "symbols_FDA = pd.merge(FDA_approvals_short, pharma_symbols, on='Company Token', how='inner', suffixes=(\"_tic\", \"_fda\"))\n",
    "symbols_FDA.head()\n",
    "print(\"symbols_FDA contains\", len(symbols_FDA.index), \"observations.\")\n"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "id": "e3d8e89b",
   "metadata": {},
   "source": [
    "This is the final cleaned data table. As can be seen, the number of observations has decreased significantly from the original drug approval data. This can be explained mainly because we're dealing with small-cap pharmaceuticals, which release drugs at much lower rates than big pharma companies. Of course, a few lost observations or untracked ones was likely caused by the data cleaning and preparation process. \n",
    "\n",
    "### 4. Collecting Price Change Data\n",
    "\n",
    "Have collected all FDA phase 3 drug approvals and matched them to their respective stocks, the leading and trailing stock values are to be found for each observation. This data is gathered using yfinance."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "id": "58701d03",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'SUPN from 2018-02-01 to 2018-04-01')"
      ]
     },
     "execution_count": 119,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[*********************100%***********************]  1 of 1 completed\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<AxesSubplot: title={'center': 'SUPN from 2018-02-01 to 2018-04-01'}, xlabel='Date'>"
      ]
     },
     "execution_count": 119,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.lines.Line2D at 0x283c44f10>"
      ]
     },
     "execution_count": 119,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 0, 'Date')"
      ]
     },
     "execution_count": 119,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Price (USD)')"
      ]
     },
     "execution_count": 119,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "start_date = '2018-02-01'\n",
    "end_date = '2018-04-01'\n",
    "observation_date = '2018-03-01'\n",
    "ticker = \"supn\"\n",
    "\n",
    "plt.title(\"{} from {} to {}\".format(ticker.upper(), start_date, end_date))\n",
    "data = yf.download(ticker,start_date, end_date)\n",
    "data['Adj Close'].plot()\n",
    "plt.axvline(x=observation_date, color='r', label=\"Approval\")\n",
    "plt.xlabel(\"Date\")\n",
    "plt.ylabel(\"Price (USD)\")\n",
    "plt.grid(which=\"major\", color='k', linestyle='-.', linewidth=0.5)\n",
    "plt.show()"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "id": "36d7c54c",
   "metadata": {},
   "source": [
    " Here is a sample plot of the yfinance collected data. One leading and one trailing month will be collected for each FDA approval observation. For this example, we take the first observation in the sample (supn) and mark the date of the observation by the red line, which may suggest very promising results in the efficacy of this hypothesis."
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "id": "06384044",
   "metadata": {},
   "source": [
    "## Analysis and Conclusion\n",
    "\n",
    "_Write text on how to perform analysis_"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "63515713",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "id": "cd22ddb3",
   "metadata": {},
   "source": [
    "## Bibliography\n",
    "\n",
    "https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases\n",
    "\n",
    "https://www.nasdaq.com/market-activity/stocks/screener\n",
    "\n",
    "https://www.drugwatch.com/fda/approval-process/\n",
    "\n",
    "https://www.fda.gov/patients/drug-development-process/step-3-clinical-research"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
